Longeveron Inc.

LGVN

Longeveron Inc.

LGVN

Insider Sentiment (TTM):

Last Purchase:2025-08-11Last Sale:2025-05-30Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:2,160,252Shares Outstanding:24,786,282,000Institutional Ownership Pct.:0.01%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets Current
Cash And Cash Equivalents At Carrying Value	10	16	5	9	10	14	19	23	12	2	5	2
Marketable Securities Current	-	-	-	-	-	-	0	0	-	0	0	2
Prepaid Expense And Other Assets Current	1	1	1	1	1	1	0	1	1	1	0	1
Accounts Receivable Net Current	0	0	0	0	0	0	0	0	0	0	0	0
Assets Current	11	17	5	10	11	15	20	24	13	4	6	5
Property Plant And Equipment Net	2	2	2	2	2	2	2	3	2	2	3	3
Intangible Assets Net Excluding Goodwill	2	2	2	2	2	2	2	2	2	2	2	3
Operating Lease Right Of Use Asset	0	0	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	15	21	10	16	17	21	26	30	19	10	12	12
Liabilities Current
Liabilities And Stockhold…
Accounts Payable Current	1	0	0	1	1	0	0	1	1	1	1	1
Accrued Liabilities Current	3	3	3	3	2	2	2	1	2	2	2	1
Loans Payable Current	-	-	-	-	-	-	-	-	-	-	-	1
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	-
Deferred Revenue Current	-	-	-	-	-	-	-	-	-	1	1	1
Contract With Customer Liability Current	0	0	0	0	0	0	0	0	0	-	1	-
Other Liabilities Current	0	0	-	-	-	-	-	-	-	-	-	-
Liabilities Current	4	4	4	5	3	3	3	3	3	5	4	3
Liabilities Noncurrent
Operating Lease Liability Noncurrent	0	0	0	0	1	1	1	1	1	1	1	2
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	-
Liabilities Noncurrent	1	1	0	1	1	1	1	1	1	1	1	2
Liabilities	5	5	5	6	4	4	4	4	4	7	5	5
Stockholders Equity
Additional Paid In Capital	153	153	138	137	132	132	131	131	116	92	92	86
Treasury Stock Value	-	-	-	-	-	-	-	-	-	-	-	-0
Retained Earnings Accumulated Deficit	-143	-137	-132	-127	-120	-115	-110	-106	-101	-89	-85	-79
Stockholders Equity	10	16	6	10	13	17	22	26	15	3	7	7
Stockholders Equity Note Subscriptions Receivable	-	-	-	-	-	-	0	0	-	-	-0	-
Liabilities And Stockholders Equity	15	21	10	16	17	21	26	30	19	10	12	12
Common Class A	-	0	0	20	-13	13	0	10	1	2	0	0
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	-0	-0	0	-	-0
Common Class B	-	1	0	0	0	1	0	0	0	1	1	0
Assets
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	-	-	0	-
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	-	-	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.31%	-8.48%	-7.02%	-	-	-	-	-	-	-	-	-
2025	-16.78%	-11.41%	12.08%	-7.91%	-8.37%	-3.02%	-17.00%	-33.38%	-26.88%	20.83%	-11.98%	-23.96%
2024	-25.18%	24.46%	107.91%	-24.52%	-29.12%	-22.22%	-9.57%	-16.96%	-33.04%	21.71%	-3.95%	-6.58%
2023	-	-	-	-	-	-	2.07%	-29.53%	-58.55%	-34.02%	-66.84%	-77.89%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.63	3.88	1.33	2.09	3.43	5.61	7.60	7.67	4.18	0.71	1.50	1.49
Quick Ratio	2.35	3.64	1.17	1.88	3.16	5.27	7.48	7.47	3.92	0.47	1.41	1.19
Working Capital	7.02M	12.51M	1.36M	5.40M	7.99M	12.55M	17.04M	20.67M	10.20M	-1.54M	1.96M	1.65M
Leverage & Debt
Debt to Equity	0.49	0.32	0.81	0.56	0.32	0.22	0.17	0.17	0.30	2.19	0.79	0.75
Interest Coverage TTM	-	-	-	-	-	-	-	-	-	-	-	-14.91
Debt Ratio	0.33	0.24	0.45	0.36	0.24	0.18	0.14	0.14	0.23	0.69	0.44	0.43
Efficiency & Turnover
Asset Turnover TTM	0.07	0.06	0.07	0.06	0.11	0.15	0.13	0.09	0.07	0.06	0.03	0.03
Days Sales Outstanding TTM	14.76	14.56	28.62	54.86	21.92	16.98	14.88	46.91	46.63	51.13	89.88	48.26
Receivables Turnover TTM	24.73	25.07	12.76	6.65	16.65	21.50	24.53	7.78	7.83	7.14	4.06	7.56
Per Share Metrics
Diluted EPS TTM	-0.75	-0.90	-1.29	-1.63	-1.81	-1.71	-2.62	-1.26	-0.00	-8.28	-9.85	-14.06
Free Cash Flow Per Share TTM	-0.67	-0.75	-1.07	-0.67	-0.69	-1.08	-1.54	-1.12	-0.00	-6.57	-8.88	-8.27
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	69.76%	65.13%	66.97%	74.81%	78.73%	82.25%	78.76%	73.06%	58.99%	48.47%	33.08%	41.74%
Operating Profit Margin TTM	-1,992.84%	-1,881.66%	-1,942.20%	-1,542.87%	-941.15%	-791.60%	-690.72%	-954.59%	-1,480.15%	-2,086.20%	-3,148.05%	-2,869.15%
Net Profit Margin TTM	-1,977.59%	-1,844.49%	-1,893.58%	-2,087.20%	-1,311.67%	-1,149.48%	-1,029.39%	-924.41%	-1,513.83%	-2,129.24%	-3,205.54%	-4,101.10%
Growth Metrics
Net Revenue Growth (1Y)	-42.74%	-45.35%	-49.87%	-22.41%	68.67%	127.51%	258.08%	155.10%	46.14%	1.45%	-35.52%	-35.41%
Net Income Growth (1Y)	-13.67%	-12.30%	-7.79%	75.19%	46.15%	22.82%	14.99%	-42.50%	-36.10%	-28.45%	-23.44%	61.40%
EPS Growth (1Y)	-58.69%	-47.10%	-50.63%	29.94%	63,272.23%	-79.35%	-73.44%	-91.06%	-99.98%	-40.13%	638.62%	1,500.53%
Valuation Metrics
P/E TTM	-0.94	-1.15	-0.39	-0.46	-0.72	-0.91	-0.66	-1.54	-563.34	-0.39	-1.38	-1.66
P/B TTM	2.12	1.61	1.57	1.38	1.54	1.35	0.74	1.03	702.90	2.69	4.39	7.47
P/S TTM	18.58	21.20	7.42	9.59	9.41	10.42	6.81	14.28	8,528.00	8.35	44.25	68.26
Market Cap	22.06M	25.78M	8.89M	13.78M	19.52M	23.17M	16.28M	26.44M	10.48B	8.17M	29.56M	49.56M
Enterprise Value	11.98M	10.02M	4.23M	4.54M	9.18M	8.85M	-2.95M	3.66M	10.47B	6.23M	24.61M	48.18M
Calculated Values
Free Cash Flow TTM	-20.91M	-18.56M	-18.89M	-12.26M	-10.42M	-16.15M	-14.52M	-15.30M	-16.58M	-16.52M	-19.30M	-17.52M
Net Debt	-10.08M	-15.76M	-4.66M	-9.24M	-10.33M	-14.33M	-19.23M	-22.78M	-12.38M	-1.94M	-4.95M	-1.38M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-08-11Purchase

Owner: Locklear, Lisa

Title: Chief Financial Officer

Shares: 11,766

Price/Share: -

Value: -

Shares Owned: 250,964

Relationship: Officer

Ownership: Direct

2025-08-11Purchase

Owner: Baluch, Khoso

Title: -

Shares: 11,766

Price/Share: -

Value: -

Shares Owned: 52,516

Relationship: Director

Ownership: Direct

2025-05-30Sale

Owner: Soffer, Rock

Title: -

Shares: 11,000

Price/Share: $1.25

Value: $13,750.00

Shares Owned: 209,034

Relationship: Director

Ownership: Direct

2025-05-22Sale

Owner: Soffer, Rock

Title: -

Shares: 2,000

Price/Share: $1.32

Value: $2,640.00

Shares Owned: 230,034

Relationship: Director

Ownership: Direct

2025-05-16Sale

Owner: Hare, Joshua

Title: Chief Scientific Officer

Shares: 5,250

Price/Share: $1.40

Value: $7,350.00

Shares Owned: 721,796

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-08-11	Locklear, Lisa	Officer	Chief Financial Officer	Direct	Purchase	11,766	-	-	250,964	4
2025-08-11	Baluch, Khoso	Director	-	Direct	Purchase	11,766	-	-	52,516	4
2025-05-30	Soffer, Rock	Director	-	Direct	Sale	11,000	1.25	$13,750.00	209,034	4
2025-05-22	Soffer, Rock	Director	-	Direct	Sale	2,000	1.32	$2,640.00	230,034	4
2025-05-16	Hare, Joshua	Director,Officer,TenPercentOwner	Chief Scientific Officer	Direct	Sale	5,250	1.40	$7,350.00	721,796	4
2024-12-02	Baluch, Khoso	Director	-	Direct	Sale	1,250	2.07	$2,587.50	23,750	4
2024-04-11	Soffer, Rock	Director	-	Direct	Purchase	31,915	2.35	$75,000.25	208,534	4
2024-04-11	Hare, Joshua	Director,Officer,TenPercentOwner	Chief Scientific Officer	Direct	Purchase	42,553	2.35	$99,999.55	633,280	4
2024-04-11	Hashad, Mohamed Wa'El Ahm…	Director,Officer	Chief Executive Officer	Direct	Purchase	10,638	2.35	$24,999.30	19,616	4
2024-01-10	Ross, Cathy	Director	-	Direct	Purchase	5,000	1.31	$6,550.00	10,000	4
2023-12-29	Baluch, Khoso	Director	-	Direct	Purchase	8,322	1.43	$11,900.46	15,000	4
2023-12-28	Pfeffer, Jeffrey	Director	-	Direct	Purchase	10,000	1.35	$13,500.00	15,000	4
2023-06-29	Clavijo, James	Officer	CFO and Treasurer	Direct	Sale	5,000	3.51	$17,550.00	47,303	4
2023-01-27	Hare, Joshua	Director,Officer,TenPercentOwner	Chief Scientific Officer	Direct	Sale	20,000	4.28	$85,600.00	7,793,263	4
2022-12-02	Hare, Joshua	Director,Officer,TenPercentOwner	Chief Scientific Officer	Direct	Sale	20,000	3.74	$74,800.00	7,813,263	4
2022-10-12	Hare, Joshua	Director,Officer,TenPercentOwner	Chief Scientific Officer	Direct	Sale	100,000	3.61	$361,000.00	7,813,263	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

0.01%

Inst. Shares: 2,160,252

Shares Outstanding: 24,786,282,000

2025-12-31

0.01%

Inst. Shares: 1,011,453

Shares Outstanding: 17,576,551,000

2025-09-30

0.01%

Inst. Shares: 986,662

Shares Outstanding: 18,373,198,000

2025-06-30

0.00%

Inst. Shares: 641,167

Shares Outstanding: 15,013,072,000

2025-03-31

0.00%

Inst. Shares: 478,606

Shares Outstanding: 14,950,734,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	2,160,252	24,786,282,000	0.01%
2025-12-31	1,011,453	17,576,551,000	0.01%
2025-09-30	986,662	18,373,198,000	0.01%
2025-06-30	641,167	15,013,072,000	0.00%
2025-03-31	478,606	14,950,734,000	0.00%
2024-12-31	432,041	9,411,164,000	0.00%
2024-09-30	262,622	13,627,793,000	0.00%
2024-06-30	330,681	6,509,881,000	0.01%
2024-03-31	49,764	2,513,587,000	0.00%
2023-12-31	2,515,058	2,173,490,000	0.12%
2023-09-30	585,366	2,117,877,000	0.03%
2023-06-30	712,304	2,110,544,000	0.03%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Longeveron Inc. (LGVN) — SEC Financial Statements & Analysis

Longeveron Inc. (LGVN) is a pharmaceutical preparations company, incorporated in DE. Longeveron Inc. trades on Nasdaq as: LGVN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Longeveron Inc. reported a -42.74% year-over-year revenue growth, a Gross Profit Margin of 69.76% (TTM), a Debt-to-Equity ratio of 0.49x, a Price-to-Sales (P/S) ratio of 18.58x (TTM), a Price-to-Book (P/B) ratio of 2.12x (TTM), at a market cap of $22.06M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -42.74%
Gross Profit Margin TTM: 69.76%
Debt To Equity: 0.49x
P/S TTM: 18.58x
P/B TTM: 2.12x
Market Cap: $22.06M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Longeveron Inc. in?

Longeveron Inc. (LGVN) operates in the Pharmaceutical Preparations industry.

What is LGVN's market cap?

Longeveron Inc. (LGVN) has a market capitalization of $22.06M as of 2026-06-30.

What exchange does LGVN trade on?

Longeveron Inc. (LGVN) trades on the Nasdaq.

Where is Longeveron Inc. incorporated?

Longeveron Inc. is incorporated in DE.

Longeveron Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Longeveron Inc. (LGVN) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Longeveron Inc. (LGVN) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.